Abacavir versus tenofovir-based first-line antiretroviral therapy and endothelial dysfunction in treatment-naive adults with HIV

Phase 4, open-label trial of abacavir and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fondazione IRCCS San Gerardo dei Tintori. Primary endpoint: Change from baseline in endothelial adhesion molecules and leukocyte activation markers. Started Nov 2009; status: completed.